MiR-193a-5p/ERBB2 act as concurrent chemoradiation therapy response indicator of esophageal squamous cell carcinoma

Concurrent chemoradiation therapy (CCRT) is the predominant treatment in esophageal cancer, however resistance to therapy and tumor recurrence are exceedingly common. Elevated ERBB2/Her2 may be at least partially responsible for both the high rates of recurrence and resistance to CCRT. This receptor...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Cheng-Han, Tsai, Chen-Hsun, Yeh, Ching-Tung, Liang, Jui-Lin, Hung, Wan-Chun, Lin, Forn-Chia, Chang, Wei-Lun, Li, Hao-Yi, Yao, Yun-Chin, Hsu, Tai-I, Lee, Yu-Cheng, Wang, Yi-Ching, Sheu, Bor-Shyang, Lai, Wu-Wei, Calkins, Marcus J., Hsiao, Michael, Lu, Pei-Jung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5129962/
https://www.ncbi.nlm.nih.gov/pubmed/27203740
http://dx.doi.org/10.18632/oncotarget.9444

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5129962/
https://www.ncbi.nlm.nih.gov/pubmed/27203740
http://dx.doi.org/10.18632/oncotarget.9444

Ejemplares similares